Nicox appoints Gavin Spencer as CEO

Spencer’s initial focus will be on securing financing to complete the Phase III trial of NCX 470, Denali

Nicox SA, an international ophthalmology company, today announced its Board of Directors has appointed the experienced biotech executive Gavin Spencer as CEO.

The appointment has immediate effect, following the Board’s decision to end the mandate of Andreas Segerros.

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.

He has spent more than 25 years in the life sciences industry and combines strong business acumen with a solid scientific background and broad strategic, financial, corporate development, commercial and operational management experience in biotechs and large pharma.

I am delighted to welcome Gavin Spencer to his new role as CEO of Nicox. Gavin brings exhaustive industry experience, particularly related to strategic partnership agreements and financing. Gavin’s initial focus will be on enabling Nicox to generate the additional data necessary for a New Drug Application for NCX 470. Gavin’s financial experience will be vital in moving this process forward, and his finesse and judgement will be equally important in our strategic and partnering discussions,” said Jean-François Labbe, Chairman of the Board of Directors of Nicox.

During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.

He has been involved in equity raising and investor relations at Nicox for many years and has led the Company’s recent financing activities.

You may also like